Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Dec 18

PMID 30555799

Citations 6

Authors

Thijs Roelofsen

Christina Wefers

Mark A J Gorris

Johannes C Textor

Leon F A G Massuger

I Jolanda M de Vries

Anne M Van Altena

Affiliations

Soon will be listed here.

Abstract

Despite advances in therapy, ovarian cancer remains the most lethal gynecological malignancy and prognosis has not substantially improved over the past 3 decades. Immunotherapy is a promising new treatment option. However, the immunosuppressive cancer microenvironment must be overcome for immunotherapy to be successful. Here, we present a unique case of spontaneous regression of ovarian carcinoma after septic peritonitis. A 79-year-old woman was diagnosed with stage IIIc ovarian cancer. The omental cake biopsy was complicated by sepsis. Although the patient recovered, her physical condition did not allow further treatment for her ovarian cancer. After 6 months, spontaneous regression of the tumor was observed during surgery. Analysis of the immune infiltrate in the tissues showed a shift from a pro-tumorigenic to an anti-tumorigenic immune response after sepsis. Strong activation of the immune system during sepsis overruled the immunosuppressive tumor microenvironment and allowed for a potent anti-tumor immune response. More understanding of immunological responses in cases with cancer and septic peritonitis might be crucial to identify potential new targets for immunotherapy.

Citing Articles

ImmuNet: a segmentation-free machine learning pipeline for immune landscape phenotyping in tumors by multiplex imaging.

Sultan S, Gorris M, Martynova E, van der Woude L, Buytenhuijs F, van Wilpe S Biol Methods Protoc. 2025; 10(1):bpae094.

PMID: 39866377 PMC: 11769680. DOI: 10.1093/biomethods/bpae094.

Impact of Sepsis on the Oncologic Outcomes of Advanced Epithelial Ovarian Cancer Patients: A Multicenter Observational Study.

Said S, de Hullu J, van der Aa M, Walraven J, Bekkers R, Slangen B Cancers (Basel). 2023; 15(18).

PMID: 37760610 PMC: 10526225. DOI: 10.3390/cancers15184642.

Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity.

Choi Y, Lichterman J, Coughlin L, Poulides N, Li W, Del Valle P Sci Immunol. 2023; 8(81):eabo2003.

PMID: 36867675 PMC: 10080670. DOI: 10.1126/sciimmunol.abo2003.

What is new about ovarian malignancies?.

Grabska K, Pilarska I, Fudalej M, Deptala A, Badowska-Kozakiewicz A Contemp Oncol (Pozn). 2022; 25(4):225-231.

PMID: 35079229 PMC: 8768052. DOI: 10.5114/wo.2021.112037.

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points.

Swiderska J, Kozlowski M, Kwiatkowski S, Cymbaluk-Ploska A Cancers (Basel). 2021; 13(23).

PMID: 34885169 PMC: 8656861. DOI: 10.3390/cancers13236063.

References

Hotchkiss R, Monneret G, Payen D . Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13(12):862-74. PMC: 4077177. DOI: 10.1038/nri3552. View

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

Thomas J, Badini M . The role of innate immunity in spontaneous regression of cancer. Indian J Cancer. 2011; 48(2):246-51. DOI: 10.4103/0019-509X.82887. View

Andersen R, Donia M, Westergaard M, Pedersen M, Hansen M, Marie Svane I . Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Hum Vaccin Immunother. 2015; 11(12):2790-5. PMC: 5054777. DOI: 10.1080/21645515.2015.1075106. View

Hobohm U, Stanford J, Grange J . Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol. 2008; 28(2):95-107. DOI: 10.1615/critrevimmunol.v28.i2.10. View

Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J . Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res. 2018; 24(14):3282-3291. PMC: 6050068. DOI: 10.1158/1078-0432.CCR-17-1805. View

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

Lai-Lai Chiang C, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N . A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013; 19(17):4801-15. PMC: 4049094. DOI: 10.1158/1078-0432.CCR-13-1185. View

Jessy T . Immunity over inability: The spontaneous regression of cancer. J Nat Sci Biol Med. 2012; 2(1):43-9. PMC: 3312698. DOI: 10.4103/0976-9668.82318. View

10.

Szajnik M, Szczepanski M, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E . TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009; 28(49):4353-63. PMC: 2794996. DOI: 10.1038/onc.2009.289. View

11.

Kleef R, Jonas W, Knogler W, Stenzinger W . Fever, cancer incidence and spontaneous remissions. Neuroimmunomodulation. 2001; 9(2):55-64. DOI: 10.1159/000049008. View

12.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F . Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018; 19(11):1468-1479. DOI: 10.1016/S1470-2045(18)30673-9. View

13.

Leentjens J, Kox M, van der Hoeven J, Netea M, Pickkers P . Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change?. Am J Respir Crit Care Med. 2013; 187(12):1287-93. DOI: 10.1164/rccm.201301-0036CP. View

14.

Boomer J, Green J, Hotchkiss R . The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. Virulence. 2013; 5(1):45-56. PMC: 3916383. DOI: 10.4161/viru.26516. View

15.

Lelubre C, Vincent J . Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol. 2018; 14(7):417-427. DOI: 10.1038/s41581-018-0005-7. View

16.

Hotchkiss R, Karl I . The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348(2):138-50. DOI: 10.1056/NEJMra021333. View

17.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

18.

Yigit R, Massuger L, Figdor C, Torensma R . Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010; 117(2):366-72. DOI: 10.1016/j.ygyno.2010.01.019. View

19.

van der Poll T, van de Veerdonk F, Scicluna B, Netea M . The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017; 17(7):407-420. DOI: 10.1038/nri.2017.36. View

20.

Rosenberg S, Spiess P, Lafreniere R . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233(4770):1318-21. DOI: 10.1126/science.3489291. View